Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
GSK & TSRO announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO.
-
GSK to divest Horlicks and other Consumer Healthcare nutrition products to Unilever
GlaxoSmithKline plc (LSE/NYSE: GSK) announces the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc.
-
Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval by Japan Ministry of Health, Labour and Welfare
The Ministry of Health, Labour and Welfare has approved Juluca Combination Tablets for the maintenance treatment of (HIV-1) infection.
-
GSK and Kyowa Hakko Kirin sign strategic commercialisation deal in Japan for daprodustat, a potential new oral treatment for anaemia associated with chronic kidney disease
Announcing a strategic collaboration for the future commercialisation of daprodustat in Japan.
-
Access to Medicine Index 2018 media statement
GSK media statement on the results of the Access to Medicine Index 2018
-
GSK submits US regulatory filing to expand the use of Nucala in children with severe eosinophilic asthma
Supplemental Biologics License Application filed indication for the use of Nucala as an add-on treatment for severe eosinophilic asthma.
-
ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine
Committee for Medicinal Products for Human Use has adopted a Positive Opinion on a Type II variation regulatory application for Tivicay
-
Once-daily Trelegy Ellipta gains expanded COPD indication in Europe
Once-daily Trelegy Ellipta now available for COPD patients requiring a step up from dual bronchodilation
-
Statement: GSK supports GOLD committee’s efforts to further personalise COPD management
Welcoming the updated Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy.
-
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir at 48 weeks in heavily treatment-experienced patients with HIV
BRIGHTE study highlights ViiV Healthcare’s commitment to developing innovative medicines for all people living with HIV
-
GSK delivers Q3 sales of £8.1 billion, +3% AER, +6% CER
Total EPS 28.8p, +16% AER, +23% CER; Adjusted EPS 35.5p, +10% AER, + 14% CER
-
ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen
FLAIR study meets primary endpoint
-
ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen
LATTE-2 study shows high rates of virologic response & long-term durability with long-acting, injectable, two-drug regimen over 160 weeks.
-
GSK announces positive phase 3 results for daprodustat in patients with anaemia associated with chronic kidney disease
Second of three pivotal studies intended to support regulatory filing in Japan in 2019
-
GSK presents new efficacy and safety data of an anti GM-CSF antibody in patients with rheumatoid arthritis
Marked patient benefit observed in phase II study supports further clinical development of GSK3196165 for RA.
-
ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
Priority review voucher used with NDA submission with anticipated target action date of six months.
-
GSK updates policy for working with healthcare professionals
We are updating our policy on working with healthcare professionals (HCPs).
-
Positive results from Harmony Outcomes study of albiglutide published in The Lancet
GSK & DCRI announced publication of positive results from the Harmony Outcomes study which assessed CV safety and efficacy of albiglutide.
-
GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study
Positive impact of innovative vaccine technology in clinical trial conducted in tuberculosis endemic regions
-
GSK and Tres Cantos Open Lab Foundation announce additional £5m funding for open innovation research in diseases impacting the developing world
Additional £5m in GSK funding to support the Foundation’s research and development programmes in diseases of the developing world.
